

GLOBAL CARE CAPITAL INC.
(FORMERLY RESINCO CAPITAL PARTNERS INC.)
CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED
JUNE 30, 2021 AND 2020
Unaudited – Prepared by Management
(Expressed in Canadian Dollars)

**NOTICE OF NO AUDITOR REVIEW
OF CONDENSED INTERIM FINANCIAL STATEMENTS**

Under National Instrument 51-102, Continuous Disclosure Requirement, if an auditor has not performed a review of the condensed interim financial statements, they must be accompanied by a notice indicating that the unaudited condensed interim financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim financial statements of Global Care Capital Partners Inc. (formerly Resinco Capital Partners Inc.) have been prepared by and are the responsibility of management. These condensed interim financial statements as at June 30, 2021 and for the six months then ended, have not been reviewed or audited by the Company's independent auditors in accordance with standards established by the Chartered Professional Accountants of Canada.

GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)
CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION
(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)

	Notes	June 30, 2021 \$	December 31, 2020 (Audited) \$
ASSETS			
Current Assets			
Cash and cash equivalents		391,257	321,608
Prepays	4	713,779	-
Investments	5	549,218	223,670
		1,654,254	545,278
Non-Current Assets			
Investments	5	28,921,773	166,669
Total assets		30,576,027	711,947
LIABILITIES			
Current Liabilities			
Accounts payable and accrued liabilities	6, 9	505,012	371,356
Loan payable	7	499,835	-
Contingent consideration liability	5, 8	-	1,700,000
Total liabilities		1,004,847	2,071,356
SHAREHOLDERS' EQUITY (DEFICIENCY)			
Share capital	8	121,905,966	96,909,265
Share-based payments reserve	8	30,139,245	23,714,464
Accumulated deficit		(122,474,031)	(121,983,138)
Total shareholders' equity (deficiency)		29,571,180	(1,359,409)
Total liabilities and shareholders' equity (deficiency)		30,576,027	711,947

Nature of operations and going concern (Note 1)

Subsequent events (Note 12)

These condensed interim financial statements were approved for issue by the Board of Directors of the Company on July 29, 2021.

They are signed on the Company's behalf by:

"Alexander Somjen"

Director

"Maciej Lis"

Director

The accompanying notes are integral to these condensed interim financial statements

GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)
CONDENSED INTERIM STATEMENTS OF NET LOSS AND COMPREHENSIVE LOSS
(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)

	Notes	Three Months Ended		Six Months Ended	
		June 30, 2021 \$	June 30, 2020 \$	June 30, 2021 \$	June 30, 2020 \$
Investment income					
Net realized loss on disposal of investments		-	-	-	8,604
Net change in unrealized gains on investments	5	177,200	(1,828)	325,547	22,989
		177,200	(1,828)	325,547	31,593
Interest income		-	2,268	-	4,512
Net investment income		177,200	440	325,547	36,105
Expenses					
Advertising and promotion		-	(831,662)	(169,145)	(831,662)
Consulting fees	9	6,236	(262,000)	(82,304)	(330,600)
Office and miscellaneous		(3,042)	(13,160)	(5,278)	(16,453)
Professional fees		(80,600)	(115,331)	(122,086)	(132,300)
Regulatory and transfer agent fees		(4,567)	(15,938)	(11,249)	(21,117)
Share-based compensation	8	(9,131)	(1,753,892)	(426,378)	(1,753,892)
Transaction cost		-	(4,300,850)	-	(4,300,850)
		(91,104)	(7,292,833)	(816,440)	(7,386,874)
Net income (loss) and comprehensive income (loss) for the period		86,096	(7,292,393)	(490,893)	(7,350,769)
Net income (loss) and comprehensive loss per share, basic and diluted		0.00	(0.13)	(0.00)	(0.24)
Weighted average number of shares outstanding, basic and diluted		244,375,908	56,495,983	228,997,219	30,553,618

The accompanying notes are integral to these condensed interim financial statements

GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)
CONDENSED INTERIM STATEMENTS OF CASH FLOWS
(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)

	Six Months Ended	
	June 30, 2021	June 30, 2020
	\$	\$
Operating activities		
Net loss and comprehensive loss for the period	(490,893)	(7,350,769)
Items not affecting cash:		
Accrued interest on loan payable	-	(4,488)
Realized loss on sale of investments	(325,547)	(8,604)
Fair value change in investments	-	(22,989)
Share-based compensation	426,378	1,753,892
Transaction costs	-	4,300,850
	(390,062)	(1,332,108)
Changes in non-cash working capital items:		
Prepaid expenses	(713,779)	(52,733)
Accounts payable and accrued liabilities	133,655	20,282
Proceeds from sale of investments	-	29,581
Net cash used in operating activities	(970,186)	(2,870)
Investing activities		
Loan receivable	-	(440,000)
Net cash used in investing activities	-	(440,000)
Financing activities		
Private placement	-	2,255,575
Exercise of options	-	125,000
Exercise of warrants	540,000	-
Proceeds from loan payable	499,835	50,000
Net cash provided by financing activities	1,039,835	2,430,575
Change in cash	69,649	655,597
Cash and cash equivalents, beginning	321,608	14,498
Cash and cash equivalents, ending	391,257	670,095
Non-cash financing activities		
Shares issued for acquisition of ASIC	\$ 11,500,000	\$ -
Shares issued to acquire 70% of HSHC	\$ -	\$ 6,885,000
Shares issued for acquisition of ViralClear	\$ -	\$ 16,920,000
Shares issued as finders fees	\$ -	\$ 1,692,000
Share issued to settle consideration payable	\$ 1,700,000	\$ -
Shares issued for acquisition of CCM	\$ 9,887,850	\$ -
Warrants issued for CCM	\$ 6,640,254	\$ -
Shares exchanged for debt	\$ 727,000	\$ -
Fair value of finders' warrants issued	\$ 24,591	\$ 1,274,545
Fair value of warrants exercised	\$ 642,048	\$ -
Fair value of finders' warrants exercised	\$ 24,394	\$ -

The accompanying notes are integral to these condensed interim financial statements

GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)
STATEMENTS OF CHANGES IN EQUITY (DEFICIENCY)
FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020
(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)

	Number of Shares	Share Capital	Share-based payments reserve	Accumulated deficit	Total Shareholders' Equity
Balance, December 31, 2019	4,893,240	\$ 53,353,405	\$ 16,849,827	\$ (68,602,875)	\$ 1,600,357
Private placement	25,000,000	2,500,000	-	-	2,500,000
Share issuance for investments	51,000,000	23,805,000	-	-	23,805,000
Shares issued as finder fees	2,400,000	1,692,000	-	-	1,692,000
Share issuance costs	-	(194,425)	-	-	(194,425)
Warrants issued as finder fees	-	(1,274,545)	1,274,545	-	-
Stock options exercised	250,000	125,000	-	-	125,000
Share based compensation	-	-	1,753,892	-	1,753,892
Transaction cost	-	-	2,608,850	-	2,608,850
Loss and comprehensive loss for the period	-	-	-	(7,350,769)	(7,350,769)
Balance, June 30, 2020	83,543,240	\$ 80,006,435	\$ 22,487,114	\$ (75,953,769)	\$ 26,539,905
Balance, December 31, 2020	105,543,240	\$ 96,909,265	\$ 23,714,464	\$ (121,983,138)	\$ (1,359,409)
Share issued to settle consideration payable	20,000,000	1,700,000	-	-	1,700,000
Warrants issued as finder fees	-	(24,591)	24,591	-	-
Shares issued for acquisition of ASIC	100,000,000	11,500,000	-	-	11,500,000
Warrants exercised	10,075,000	1,157,048	(642,048)	-	515,000
Finders' warrants exercise	250,000	36,894	(24,394)	-	25,000
Shares issued to CCM Technologies	94,170,001	9,887,850	6,640,254	-	16,528,104
Shares for debt	8,077,774	727,000	-	-	727,000
Share based compensation	-	-	426,378	-	426,378
Loss and comprehensive loss for the period	-	-	-	(490,893)	(490,893)
Balance, June 30, 2021	338,116,015	\$ 121,905,966	\$ 30,139,245	\$ (122,474,031)	\$ 29,571,180

The accompanying notes are integral to these condensed interim financial statements

GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020
(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)

1. NATURE OF OPERATIONS AND GOING CONCERN

Global Care Capital Inc., formerly Resinco Capital Partners Inc. (“Global Care Capital” or the “Company”) was incorporated under the laws of British Columbia on May 25, 2004. On April 13, 2020, the Company changed its name from Resinco Capital Partners Inc. to Global Care Capital Inc. The Company’s shares are listed for trading on the Canadian Securities Exchange (“CSE”) under the ticker symbol HLTH, the Frankfurt Stock Exchange under the symbol L6V1.F and in the US on the OTC market, under the symbol RSCZF. The registered office of the Company is Suite 810 – 789 West Pender Street, Vancouver, British Columbia, Canada, V6C 1H2.

Global Care Capital is a global investment company which provides early-stage financing to private and public companies in the medical marijuana, pharmaceutical, technology, cryptocurrency, and mining sectors. The Company focuses on early-stage investment opportunities in underdeveloped assets by acquiring significant positions in these early-stage investment companies.

These condensed interim financial statements have been prepared on a going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at June 30, 2021, the Company has a working capital of \$649,407 (December 31, 2020 -working capital deficit of \$1,526,078 and accumulated deficit of \$122,474,031 (December 31, 2020 - \$121,983,138). These factors indicate the existence of a material uncertainty that may raise significant doubt about the Company’s ability to continue as a going concern. The continued operations of the Company are dependent on its ability to generate cash flows from additional equity financing and/or through the sales of investments. These condensed interim financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern, in which case such adjustments could be material.

In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. COVID-19 and new variants of the disease have adversely affected workforces, economies, and financial markets globally. To date, the Company has not experienced any adverse impact to its financial performance or cash flow as a result of Covid-19 or new variants. The impact and duration of COVID-19 and new variants are unknown at this time and it is not possible to estimate the impact the length and severity of these developments will have on the financial results and condition of the Company in future periods.

2. BASIS OF PRESENTATION AND STATEMENT OF COMPLIANCE

Statement of compliance

These condensed interim financial statements have been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting (“IAS 34”) as issued by the International Accounting Standards Board (“IASB”). The policies applied in these condensed interim financial statements are based on International Financial Reporting Standards (“IFRS”) issued and outstanding as at the date the Board of Directors approved these condensed interim financial statements for issue.

These condensed interim financial statements do not include all of the information and disclosures required by IFRS for annual financial statements and therefore should be read in conjunction with the Company’s annual financial statements for the year ended December 31, 2020.

GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020
(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)

2. BASIS OF PRESENTATION AND STATEMENT OF COMPLIANCE (continued)

Basis of presentation

These condensed interim financial statements have been prepared on the historical cost basis except for certain financial instruments which are measured at fair value. In addition, these condensed interim financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

On March 13, 2020, the Company completed a share consolidation of its share capital on the basis of twenty-five (25) existing common shares for one (1) new common share. As a result of the share consolidation, the 122,331,000 common shares issued and outstanding were consolidated to 4,893,240 common shares. All common shares and per share amounts have been restated to give effect to the share consolidation (Note 8).

For the period ended June 30, 2020, the Company has changed the presentation of cash inflows relating to proceeds from the sale of investments from investing activities to operating activities in the statement of cash flows to reflect the economic substance of transactions.

Functional and presentation currency

These condensed interim financial statements are presented in Canadian Dollars, which is the Company's functional and presentation currency.

Use of estimates and judgments

The preparation of the condensed interim financial statements requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed interim financial statements and reported amounts of expenses during the reporting period. Actual outcomes could differ from these estimates. The condensed interim financial statements include estimates which, by their nature, are uncertain. The impact of such estimates is pervasive throughout the condensed interim financial statements, and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and future periods if the revision affects both current and future periods. These estimates are based on historical experience, current and future economic conditions and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Information about critical judgments in applying accounting policies and sources of estimation uncertainty that have the most significant risk of causing material adjustment to the carrying amounts of assets and liabilities recognized in the condensed interim financial statements within the next financial year are the same as those that applied to the Company's 2020 audited financial statements.

3. SIGNIFICANT ACCOUNTING POLICIES

The condensed interim financial statements have been prepared using accounting policies consistent with those used in the Company's 2020 audited financial statements. These condensed interim financial statements should be read in conjunction with the audited financial statements of the Company as at and for the year ended December 31, 2020.

4. PREPAIDS

During the period ended June 30, 2021, the company paid a \$713,779 (EUR \$460,000) deposit in connection with a Streaming Agreement between the Company and ASIC Power Company ("ASIC").

GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020
(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)

5. INVESTMENTS

At June 30, 2021, the Company held the following investments:

Investee	Number of Shares	Cost \$	Fair Value \$
Public Companies			
Metaverse Capital Corp.	5,058,583	101,172	-
180 Life Sciences Corp	44,240	272,000	548,000
Total of 2 other public company investments, each valued under \$15,000		40,598	1,218
		413,770	549,218
Private Companies			
ASIC Power Company	10,000,000	11,500,000	11,500,000
1290369 B.C, Ltd. d/b/a CCM Technologies.	94,170,001	17,255,104	17,255,104
Pembrook Copper Corp.	320,000	452,000	1
Vancity Green List Inc.	100	1,200,000	-
High Standard Health Care Ltd.	27,000,000	6,885,000	-
ViralClear Rapid Test Corp.	24,000,000	30,554,645	166,668
Healthview Technologies Inc.	20,000,000	3,250,000	-
360 Life Sciences Corp.	800,000	10,750,000	-
		81,846,749	28,921,773
		82,260,519	29,470,991

At December 31, 2020, the Company held the following investments:

Investee	Number of Shares	Cost \$	Fair Value \$
Public Companies			
Global Gaming Technologies Corp.	720,000	575,111	63,253
Metaverse Capital Corp.	5,058,583	101,172	-
180 Life Sciences Corp	44,240	272,000	153,771
Total of 2 other public company investments, each valued under \$15,000		40,598	6,646
		988,881	223,670
Private Companies			
Pembrook Copper Corp.	320,000	452,000	1
Vancity Green List Inc.	100	1,200,000	-
High Standard Health Care Ltd.	27,000,000	6,885,000	-
ViralClear Rapid Test Corp.	24,000,000	30,554,645	166,668
Healthview Technologies Inc.	20,000,000	3,250,000	-
360 Life Sciences Corp.	800,000	10,750,000	-
		53,091,645	166,669
		54,080,526	390,339

GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020
(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)

5. INVESTMENTS (continued)

Healthview Technologies Inc.

On September 14, 2020, the Company acquired all of the issued and outstanding securities in the capital of Healthview Technologies Inc. ("Healthview") in exchange for 20,000,000 common shares of the Company with an estimated fair value of \$1,300,000 and 20,000,000 contingently issuable shares with an estimated fair value of \$1,950,000. Healthview provides wellness support and mental health solutions and services to both employers and employees. As at December 31, 2020, the contingent consideration liability was re-measured to \$1,700,000. As at June 30, 2021, the estimated fair value of Healthview was \$Nil (December 31, 2020 - \$Nil).

During the period ended June 30, 2021, Healthview achieved its two earn-out milestones by onboarding its first customers across the retail, hospitality, medical, finance and transportation industries and by generating revenue. As a result, the Company issued 20,000,000 common shares (the "Earn-Out Shares") with a fair value of \$1,700,000. The Earn-Out Shares will not be subject to any hold period under applicable securities laws.

360 Life Sciences Corp.

On August 4, 2020, the Company sold all of the issued and outstanding shares of its wholly-owned subsidiary ReFormation Pharmaceuticals Corp. ("ReFormation") to 360 Life Sciences Corp. (the "Purchaser") pursuant to the share purchase agreement between Global Care and the Purchaser signed on June 24, 2020. The Purchaser acquired all the issued and outstanding shares of ReFormation in exchange for 800,000 common shares of the Purchaser with an estimated fair value of \$Nil. As at June 30, 2021, the estimated fair value of 360 Life Sciences Corp. was \$Nil.

High Standard Health Care Ltd.

On June 5, 2020, the Company acquired 70% of High Standard Health Care Ltd. ("HSHC") in exchange for 27,000,000 of the Company's common shares with an estimated fair value of \$6,885,000. HSHC specializes in procuring personal protective equipment ("PPE") including but not limited to respiratory masks, hand sanitizer, gowns, infrared thermometers and face shields and has been active in procurement during COVID-19 for hospitals, municipalities, long-term care facilities, fire departments and police departments.

Under the agreement, the Company will pay \$5,000,000 in cash or by the issue common shares ("Performance Shares") at the discretion of the Company at the time a Milestone Target is met for every \$14,300,000 in gross revenue generated by HSHC, effective upon HSHC reaching \$21,430,000 in revenue ("Milestone Targets") up to a maximum of \$286,000,000 in gross revenue or 20 Milestone Targets on or before May 31, 2025 for total value of up to \$100,000,000 if all Milestone Targets are achieved. The Company may issue up to 26,500,000 Payment Shares in satisfaction of met Milestone Targets. The Company recognized a contingent consideration liability with an estimated fair value of \$500,000. As at December 31, 2020, the contingent consideration liability was re-measured to \$nil. As at December 31, 2020, management determined that the investment in HSHC was not expected to be recoverable and reduced the estimated fair value of the investment to \$Nil.

ViralClear Rapid Test Corp.

On April 17, 2020, the Company acquired 100% interest in ViralClear Rapid Test Corp. ("ViralClear") in exchange for 24,000,000 of the Company's common shares with an estimated fair value of \$30,554,645. The Company paid finders' fees to an arm's-length party of 2,400,000 common shares with an estimated fair value of \$3,055,465. As at December 31, 2020, the fair value of the investment was adjusted to its estimated fair value of \$166,668, using a net asset approach. As at June 30, 2021, the estimated fair value of ViralClear is \$166,668.

GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020
(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)

5. INVESTMENTS (continued)

180 Life Sciences Corp.

On November 6, 2020, the Company acquired 100% of 180 Life Sciences Corp (“180 Life Sciences”) by exchanging 263 CannaBioRX shares owned the Company for 44,240 180 Life Sciences shares at a fair value of \$153,771. As at June 30, 2021, the fair value of 180 Life Sciences is \$548,000 (December 31, 2020 - \$153,771). The Company recorded an unrealized gain on investments of \$394,229 for the period ended June 30, 2021.

Vancity Green List Inc.

On December 28, 2018, the Company acquired 100% of Vancity Green List Inc. (“Vancity”) by way of a three-cornered amalgamation. Vancity is a website application that connects personal use cannabis growers and local dispensaries. In consideration, the Company issued 600,000 common shares with a fair value of \$1,200,000. As at June 30, 2021, the fair value of Vancity was \$Nil. (December 31, 2020 - \$Nil)

ASIC Power Company

On January 28, 2021, the Company acquired all of the issued and outstanding securities in the capital of ASIC in exchange for 100,000,000 common shares of the Company with a fair value of \$11,500,000 issued to ASIC shareholders. ASIC is a cryptocurrency company combining state of the art ASIC chips with royalty streaming contracts.

12903609 B.C. Ltd. d/b/a CCM Technologies

On June 2, 2021, the Company acquired 100% of the issued and outstanding common shares and warrants of 1290369 B.C. Ltd. d/b/a CCM Technologies Inc. (“CCM”) by way of a share exchange agreement. The Company issued 94,170,001 common shares to the shareholders and issued 65,000,000 common share purchase warrants to the CCM warrant holders. Each warrant provides the holder with an option to purchase one common share of the Company at a price of \$0.05 and 50,000,000 warrants expire on March 1, 2023 and 15,000,000 warrants expire on April 20, 2023. There is no hold period for the shares or warrants pursuant to applicable securities laws, however, 89,170,001 shares will be subject to voluntary hold periods (the “Voluntary Restrictions”) with 44,170,000 being released on the date that is 4 months from June 2, 2021 (the “Closing Date”), being October 3rd, 2021, and 7,500,000 common shares being released semi-annually over a three-year period from the Closing Date.

6. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

The Company’s accounts payable and accrued liabilities are as follows:

	June 30, 2021	December 31, 2020
	\$	\$
Trade payables	200,287	97,206
Accrued liabilities	304,725	274,150
Total	505,012	371,356

7. LOAN PAYABLE

During the period ended June 30, 2021, the Company received unsecured loan proceeds of \$499,835 (December 31, 2020 - \$Nil) from arms-length parties. These loans are unsecured, non-interest bearing and due on demand.

GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020
(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)

8. SHARE CAPITAL

a) Authorized share capital

At June 30, 2021, the authorized share capital comprised an unlimited number of common shares without par value.

b) Issued share capital

At June 30, 2021, the Company had 338,116,015 (December 31, 2020 – 105,543,240) common shares issued and outstanding.

During the period ended June 30, 2021:

On January 28, 2021, the Company issued 100,000,000 common shares of the Company to ASIC shareholders. On completion of the acquisition of all of the issued and outstanding securities in the capital of ASIC with a fair value of \$11,500,000 (Note 5).

On February 2, 2021, the Company issued 10,000,000 common shares to Healthview with a fair value of \$900,000 in connection in achieving the first earn-out milestone whereby they onboarded their first customers across the retail, hospitality, medical, finance and transportation industries to offer Mental Health Services (Note 5).

On March 4, 2021, the Company issued 10,000,000 common shares to Healthview with a fair value of \$800,000 in connection with achieving its second and final of two earn-out milestones by generating revenue (Note 5).

During the period ended June 30, 2021, the Company issued 10,075,000 common shares for total proceeds of \$515,000 pursuant to warrants exercised. In addition, \$642,048 representing the fair value of the warrants was re-allocated from share-based payment reserve to share capital.

During the period ended June 30, 2021, the Company issued 250,000 common shares for total proceeds of \$25,000 pursuant to the exercise of finder's warrants exercised. In addition, \$24,394 representing the fair value of the finder's warrants was re-allocated from share-based payments reserves to share capital.

During the period ended June 30, 2021, the Company issued 94,170,001 common shares with a fair value of \$9,877,850 and 65,000,000 common share purchase warrants to the shareholders of CCM (Note 5).

During the period ended June 30, 2021, the Company issued 8,077,774 common shares with a fair value of \$605,833 to a creditor assumed by the Company pursuant to the terms of the agreement between CCM and the Company.

During the year ended December 31, 2020:

During the year ended December 31, 2020, the Company issued 25,000,000 common shares for gross proceeds of \$2,500,000 pursuant to private placements and issued 250,000 common shares for gross proceeds of \$125,000 from the exercise of stock options.

On September 15, 2020, the Company issued 20,000,000 common shares, with a fair value of \$1,300,000 to acquire 100% of Healthview. The Company also issued 2,000,000 common shares for a fair value of \$130,000 for finder's fee pursuant to the acquisition.

On June 5, 2020, the Company issued 27,000,000 common shares, with a fair value of \$6,885,000 to acquire 70% of HSHC.

GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020
(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)

8. SHARE CAPITAL (continued)

b) Issued share capital (continued)

On April 17, 2020, the Company issued 24,000,000 of the Company's common shares with a fair value of \$30,000,000 to acquire 100% interest in ViralClear. The Company has also issued an aggregate 2,400,000 common shares with a fair value of \$3,000,000 to an arm's-length party as payment of finder's fees.

On April 9, 2020, the Company closed a non-brokered private placement consisting of 25,000,000 common shares and 12,500,000 warrants for gross proceeds of \$2,500,000. Each whole warrant is convertible into one common share. The consideration for the private placement consisted of \$2,450,000 in cash and a \$50,000 debt settlement. The Company paid \$194,425 in finders' fee and issued 1,944,250 finder warrants with a fair value of \$189,715, calculated using the Black-Scholes pricing model with the following assumptions: term of 2 years; expected volatility of 318%; risk-free rate of 0.40%; and expected dividends of zero. The Company re-allocated \$189,715 from share capital to share-based payments reserve.

c) Stock options – Directors, officers, employees and consultants

The Board of Directors of the Company may from time-to-time grant to directors, officers, employees and consultants of the Company, non-transferable options to purchase common shares, provided that the number of common shares reserved for issuance will not exceed 10% of the issued and outstanding common shares, exercisable for a period of up to five years from the date of grant. The Company's stock option plan requires that options vest 20% immediately, with 20% vesting every nine months thereafter; however, the Board may change such provisions at its discretion or as required on a grant-by-grant basis.

The continuity for stock options granted to directors, officers, employees and consultants of the Company for the period ended June 30, 2021 is as follows:

Grant Date	Expiry date	Number of options	Exercise price
June 22, 2018	June 22, 2023	156,560	\$ 5.500
April 9, 2020	April 9, 2022	2,299,463	0.660
April 17, 2020	April 15, 2022	500,000	0.200
April 17, 2020	April 15, 2022	2,150,000	0.500
June 5, 2020	June 5, 2022	1,000,000	0.290
February 4, 2021	February 4, 2026	3,650,000	0.115
June 23, 2021	June 23, 2026	1,500,000	0.080
June 23, 2021	June 23, 2026	1,250,000	0.030
June 23, 2021	June 23, 2026	1,250,000	0.075
Balance at June 30, 2021		13,756,023	\$ 0.410

	Number of options	Weighted average exercise price
Balance at December 31, 2020	6,106,023	\$ 0.630
Options granted	7,650,000	0.240
Options exercised	-	-
Options cancelled and expired	-	-
Balance at June 30, 2021	13,756,023	\$ 0.410

GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020
(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)

8. SHARE CAPITAL (continued)

c) Stock options – Directors, officers, employees and consultants (continued)

The continuity for stock options granted to directors, officers, employees and consultants of the Company for the year ended December 31, 2020 is as follows:

	Number of options	Weighted average exercise price
Balance at December 31, 2019	164,560	\$ 5.50
Options granted	6,199,463	0.50
Options exercised	(250,000)	0.50
Options cancelled and expired	(8,000)	5.50
Balance at December 31, 2020	6,106,023	\$ 0.63

On February 4, 2021, the Company granted 3,650,000 stock options with an exercise price of \$0.115 per share expiring on February 4, 2026. The fair value of the stock options was estimated to be \$417,247 using the Black-Scholes pricing model with the following assumptions: term - 5 years; expected volatility – 267.40%; risk-free rate - 0.32%; and expected dividends - zero.

On June 23, 2021, the Company granted 4,000,000 incentive stock options to an officer of the Company. 1,500,000 options are exercisable at a price of \$0.08 per Share; 1,250,000 options are exercisable at a price of \$0.30 per share; and 1,250,000 options are exercisable at a price of \$0.75 per Share. The options will vest as to 50% every six (6) months and have an expiry date of June 23, 2026. The fair value of the stock options was estimated to be \$317,970 using the Black-Scholes pricing model with the following assumptions: term - 5 years; expected volatility – 261%; risk-free rate - 0.86%; and expected dividend yield- 0%.

d) Finders' warrants

The continuity for finders' warrants for the period ended June 30, 2021 is as follows:

	Number of warrants	Weighted average exercise price
Balance at December 31, 2020	1,944,250	\$ 0.10
Warrants granted	125,000	0.20
Warrants exercised	(250,000)	0.10
Balance at June 30, 2021	1,819,250	\$ 0.22

The continuity for finders' warrants for the year ended December 31, 2020 is as follows:

	Number of warrants	Weighted average exercise price
Balance at December 31, 2019	-	\$ -
Warrants granted	1,944,250	0.10
Balance at December 31, 2020	1,944,250	\$ 0.10

On February 21, 2021, the Company issued 125,000 finder's warrants with an exercise price of \$0.20 per share expiring on April 9, 2022 in connection with a private placement completed on April 9, 2020. The 125,000 finder's warrants remained exercisable on June 30, 2021. The fair value of the finder's warrants was estimated to be \$24,591 using the Black-Scholes pricing model with the following assumptions: term – 1.13 years; expected volatility – 308.48%; risk-free rate - 0.41%; and expected dividend yield - 0%

GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020
(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)

8. SHARE CAPITAL (continued)

e) Warrants

The continuity for warrants for the period ended June 30, 2021 is as follows:

	Number of warrants	Weighted average exercise price
Balance at December 31, 2020	25,500,000	\$ 0.16
Warrants granted	65,000,000	0.05
Warrants exercised	(10,075,000)	0.16
Warrants expired	(3,000,000)	0.38
Balance at June 30, 2021	77,425,000	\$ 0.07

The continuity for warrants for the year ended December 31, 2020 is as follows:

	Number of warrants	Weighted average exercise price
Balance at December 31, 2019	-	\$ -
Warrants granted	25,500,000	0.16
Balance at December 31, 2020	25,500,000	\$ 0.16

On June 2, 2021, the Company issued 65,000,000 warrants with an exercise price of \$0.05. 50,000,000 warrants expire on March 1, 2023 and 15,000,000 warrants expire on April 20, 2023. The fair value of the warrants was determined to be \$6,640,254 calculated using the Black-Scholes Option Pricing Model with the following assumptions: expected life of options – 1.74-1.88 years; expected volatility – 316.29%; expected dividend yield – 0%; and risk-free rate – 0.32%.

9. RELATED PARTY TRANSACTIONS AND BALANCES

The following directors and/or senior officers transacted with the Company in the reporting year. The terms and conditions of the transactions with key management personnel and their related parties were no more favourable than those available, or which might reasonably be expected to be available, on similar transactions to non-key management personnel related entities on an arm's length basis. The aggregate value of transactions relating to key management personnel were as follows:

	June 30, 2021	June 30, 2020
	\$	\$
Consulting fees paid to a company controlled by the CEO	67,800	101,700
Consulting fees paid to the CFO	3,000	1,575
Corporate fees paid to a company controlled by the former corporate secretary	-	3,125
Consulting and accounting fees and rent paid to companies controlled by the former CFO	-	6,850
Share-based compensation	369,221	-
Total	440,021	113,250

As at June 30, 2021, there was \$175,150 (December 31, 2020 - \$273,850) due to current and former officers and management of the Company.

On January 17, 2020, the Company entered into a loan agreement in the amount of \$50,000 with a company jointly controlled by the former corporate secretary and CFO. The loan was due on demand and interest accrued on the principal amount at the rate of 8% per annum. On April 9, 2020, the loan was settled with common shares of the Company.

GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020
(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)

10. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

Financial instruments

The Company's financial instruments consist of cash and cash equivalents, loans receivable, investments, accounts payable and accrued liabilities and contingent consideration liability. The carrying value of loans receivable and accounts payable and accrued liabilities approximates their fair value due to the short-term nature. Cash and cash equivalents and contingent consideration liability are recorded at fair value using Level 1 of the fair value hierarchy. As at June 30, 2021, investments in public companies of \$549,218 (December 31, 2020 - \$223,670) are recorded at fair value using Level 1 of the fair value hierarchy and investments in private companies of \$28,921,773 (December 31, 2020 - \$166,669) are recorded at fair value using level 2 of the fair value hierarchy.

The Company's financial instruments recorded at fair value require disclosure about how the fair value was determined based on significant levels of inputs described in the following hierarchy:

- Level 1 - Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions occur in sufficient frequency and value to provide pricing information on an ongoing basis.
- Level 2 - Pricing inputs are other than quoted prices in active markets included in Level 1. Prices in Level 2 are either directly or indirectly observable as of the reporting date. Level 2 valuations are based on inputs including quoted forward prices for commodities, time value and volatility factors, which can be substantially observed or corroborated in the market place.
- Level 3 - Valuations in this level are those with inputs for the asset or liability that are not based on observable market data.

The following table presents the Company's financial instruments, measured at fair value on a recurring basis on the statements of financial position and categorized into levels of the fair value hierarchy:

	Level 1	Level 2	Level 3	Total
June 30, 2021	\$	\$	\$	\$
Cash and cash equivalents	391,257	-	-	391,257
Investments	549,218	28,921,773	-	29,470,991
December 31, 2020	\$	\$	\$	\$
Cash and cash equivalents	321,608	-	-	321,608
Investments	223,670	166,669	-	390,339
Contingent consideration liability	-	-	1,700,000	1,700,000

There were no transfers between levels during the period.

GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020
(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)

10. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (continued)

Financial Instruments (continued)

The following table reconciles the Company's Level 3 fair value investments:

Level 3	Period ended June 30, 2021	Year ended December 31, 2020
	\$	\$
Balance, beginning	-	462,001
Additions	-	40,641,687
Net change in unrealized gain (loss) on investments	-	(41,103,688)
Balance, ending	-	-

Risk management

The Company is or may be subject to certain risks including interest rate risk, currency risk, credit risk and market risk. Risk management strategies may expose the Company to further gains or losses, but serve to stabilize future cash flows, reduce the volatility of operating results and increase overall financial strength.

Currency risk

The Company has foreign investments and is therefore subject to currency risk. Management believes these investment and transaction amounts are not significant and there are no material foreign currency commitments. The currency risk is therefore manageable and not significant. The Company does not currently use any derivative instruments to reduce its exposure to fluctuations in foreign currency exchange rates.

Credit risk

Credit risk is the risk associated with the inability of a third party to fulfil its payment obligations. The Company is exposed to the risk that third parties that owe money or securities in connection with services provided, or for other purposes, will default on their underlying obligations.

Prior to accepting any service engagement or providing any loan, the Company assesses future recoverability by examining the entities' financial conditions, properties and assets, business development activities and management. The Company manages its exposure to credit risk by reviewing the outstanding balances on an ongoing basis, monitoring the amount attributable to each counterparty and the length of time taken for amounts to be settled. Where necessary, management takes appropriate action to follow up on those balances considered overdue.

GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020
(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)

10. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (continued)

Risk management (continued)

Liquidity risk

Liquidity risk is the risk that the Company will have insufficient cash resources to meet its financial obligations as they become due. The Company's liquidity and operating results may be adversely affected if the Company does not have access to the capital markets, whether as a result of a downturn in general market conditions or related to matters specific to the Company, or if the value of the Company's investments decline, resulting in lower proceeds and/or losses on disposition. The Company generates cash flows primarily from the disposition of its investments and from its financing activities.

The Company's investments focus on early-stage companies which can at times be relatively illiquid and if the Company decides to dispose of certain securities, it may not be able to do so at favorable prices at that time, or at all. However, the Company has sufficient marketable securities which are freely tradable and relatively liquid to fund its obligations as they become due under normal operating conditions such that, in the absence of overall market disruptions or exceptional circumstances, liquidity risk can be minimized.

The Company expects accounts payable and accrued liabilities and contingent consideration liabilities to be settled within 12 months of June 30, 2021.

Market risk

Market risk is the risk that the fair value of, or future cash flows from, the Company's financial instruments will significantly fluctuate due to changes in market prices. The value of the financial instruments can be affected by changes in interest rates, foreign exchange rates and equity and commodity prices. The Company is exposed to market risk in trading its investments and unfavourable market conditions could result in dispositions of investments at less than favourable prices. The Company's investments are primarily concentrated in early-stage companies, which results in exposure to higher volatility than broader market investments and indexes. The Company's investments are accounted for at fair value and are sensitive to changes in market bid prices, such that changes in market prices result in a proportionate change in the carrying value of the Company's investments. A 10% change in the fair values of the Company's investments at June 30, 2021 would have a \$2,947,099 (2020 - \$2,429,286) impact on operations.

Concentration risk

The Company is subject to concentration risk due to the nature of the Company's operations as an investment company and the number of investments held in the portfolio which consists primarily of early stage companies and their related technologies. As a result, the investment portfolio is directly exposed to the risks associated with companies operating in these industry sectors.

As at June 30, 2021, approximately 99.9% (December 31, 2020 - 82%) of the fair value of the Company's investment portfolio consisted of investments in four (December 31, 2020 - two) companies with the largest single investment comprising 59% (December 31, 2020 - 43%) of the total portfolio value.

GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020
(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)

11. MANAGEMENT OF CAPITAL

The Company considers its common shares and options to comprise its capital.

The Company's objectives when managing capital are:

- (a) To ensure that the Company maintains the level of capital necessary to meet its operational requirements;
- (b) To allow the Company to respond to changes in economic and/or marketplace conditions by maintaining its ability to purchase new investments;
- (c) To create sustained growth in shareholder value by increasing shareholders' equity and minimizing shareholder dilution; and
- (d) To maintain a flexible capital structure that optimizes the cost of capital at acceptable levels of risk.

The Company manages its capital structure and makes adjustments to it in the light of changes in economic conditions and the risk characteristics of its underlying assets. The Company maintains or adjusts its capital level to meet its objectives, in order of preference, by:

- (a) Realizing proceeds from the disposition of investments and provision of corporate services; and
- (b) Raising funds through equity financings.

The Company is not subject to any externally imposed capital requirements. Management monitors the Company's capital to ensure capital resources will be sufficient to discharge its liabilities on an ongoing basis.

12. SUBSEQUENT EVENTS

The Company granted 4,000,000 incentive stock options to an officer of the Company. 2,500,000 options are exercisable at a price of \$0.06 per Share; 750,000 options are exercisable at a price of \$0.30 per Share; and 750,000 options are exercisable at a price of \$0.75 per Share. The options will vest as to 50% every six (6) months. These options have an expiry date of July 12, 2026.

Pursuant to a settlement of debt under promissory note, the Company issued 541,538 common shares of the Company (the "Shares") at a deemed price of \$0.065 per share to the holder of the promissory note. All securities issued in connection with the debt settlement will be subject to a statutory hold period which will expire on the date that is four months and one day from the date of issuance.